PX1 Research provides ultra-pure CJC-1295 with DAC (Drug Affinity Complex) engineered specifically for qualified academic, medical, and scientific research institutions. Synthesized in US-based GMP-compliant facilities under ISO 17025 quality systems, our research peptides undergo batch-specific HPLC and Mass Spectrometry validation. Laboratory investigators searching for reliable procurement channels can access complete analytical documentation and dependable same-day fulfillment.
PX1 Research provides ultra-pure CJC-1295 with DAC (Drug Affinity Complex) engineered specifically for qualified academic, medical, and scientific research institutions. Synthesized in US-based GMP-compliant facilities under ISO 17025 quality systems, our research peptides undergo batch-specific HPLC and Mass Spectrometry validation. Laboratory investigators searching for reliable procurement channels can access complete analytical documentation and dependable same-day fulfillment.
When searching for cjc 1295 dac vendita online, laboratory procurement specialists require verified analytical purity, lot-specific HPLC/MS chromatograms, and guaranteed endotoxin compliance (<0.01 EU/mg). CJC-1295 DAC is a synthetic 29-amino acid GHRH analog bioconjugated with a maleimido derivative, designed for extended plasma half-life in preclinical research models evaluating sustained GH and IGF-1 secretion.
Because international market inquiries under terms such as cjc 1295 dac vendita online often connect researchers with variable non-regulated suppliers, securing verified material from an accredited domestic manufacturer is critical to experimental reproducibility. PX1 Research delivers standardized, analytical-grade CJC-1295 with DAC accompanied by transparent third-party testing for rigorous in vitro and animal assays.
CJC-1295 with DAC is a modified, truncated 29-amino acid sequence derived from human Growth Hormone-Releasing Hormone (GHRH 1-29), optimized for enhanced structural stability. The primary peptide backbone incorporates specific D-amino acid substitutions—namely D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—designed to render the peptide resistant to rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV).
The critical distinguishing feature of this compound is the Drug Affinity Complex (DAC) moiety: a 3-maleimidopropionic acid linker covalently appended to the C-terminal lysine residue. In biological fluid or systemic circulation, this maleimide group selectively binds to free cysteine-34 residues on endogenous serum albumin. This bioconjugation shields the peptide from renal clearance and enzymatic degradation, effectively extending the biological half-life from a few minutes (typical of native GHRH) to approximately 6 to 8 days in rodent and non-human primate research models.
In preclinical investigations examining pituitary hormone signaling pathways, researchers frequently evaluate CJC-1295 with DAC alongside short-acting GHRH analogs such as CJC-1295 Without DAC (also designated as Modified GRF 1-29) and Sermorelin. Unmodified GHRH structures require frequent administration in animal models due to rapid enzymatic clearance, yielding transient, pulsatile growth hormone spikes. In contrast, CJC-1295 DAC promotes sustained, baseline elevation of GH secretion.
Furthermore, researchers studying complex neuroendocrine regulation often pair GHRH analogs with selective growth hormone secretagogue receptor (GHSR-1a) agonists. Compounds such as Ipamorelin, GHRP-2, and GHRP-6 stimulate GH release via pathways distinct from GHRH. Combining these classes in controlled preclinical assays allows investigators to analyze receptor synergy, biphasic GH secretion dynamics, and downstream signaling without non-specific elevation of ACTH, cortisol, or prolactin.
The primary focus of preclinical inquiry involving CJC-1295 DAC centers on the somatotropic axis. By binding to GHRH receptors on pituitary somatotropes, the compound stimulates endogenous synthesis and release of growth hormone (GH). In rodent models, continuous GHRH receptor activation produces a persistent increase in systemic GH concentrations, which subsequently stimulates hepatic expression and circulating levels of Insulin-like Growth Factor 1 (IGF-1).
Investigative literature highlights several key areas of preclinical exploration:
• Cellular Regeneration and Tissue Repair: Evaluating the downstream impact of elevated IGF-1 on protein translation, cellular proliferation, and extracellular matrix remodeling in musculoskeletal tissue models. Researchers studying repair mechanisms often cross-reference these findings with connective tissue peptides like BPC-157 and TB-500.
• Metabolic Dynamics: Analyzing adipocyte lipolysis, lipid oxidation, and glucose utilization under conditions of sustained growth hormone elevation.
• Age-Related Somatopause Models: Investigating whether prolonged somatotrope stimulation can reverse senescent declines in pituitary function in aging rodent subjects.
All findings documented in scientific literature derive strictly from controlled in vitro assays or animal research; clinical applications or human therapeutic outcomes remain outside the scope of research-grade materials.
Navigating international channels for cjc 1295 dac vendita online requires careful vetting of technical specifications. Substandard reagents containing residual solvents, truncated synthesis sequences, or bacterial endotoxins can invalidate cell culture viability and introduce confounding variables into animal research.
PX1 Research enforces strict quality control parameters across our complete catalog of research peptides. Every production lot must satisfy seven core analytical benchmarks before release:
1. Purity Threshold: Minimum 99.0% purity determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).
2. Identity Confirmation: Molecular weight verified via Electrospray Ionization Mass Spectrometry (ESI-MS).
3. Endotoxin Quantitation: Certified <0.01 EU/mg via Chromogenic Recombinant Factor C (rFC) assays.
4. Residual Solvent Analysis: Complete removal of TFA, acetonitrile, and synthesis reagents confirmed via Gas Chromatography.
5. US Manufacturing Compliance: Synthesized in ISO 17025 accredited, US-based GMP facilities.
6. Lot Traceability: Individual lot codes linked to publicly accessible, downloadable Certificates of Analysis.
7. Cold-Chain Fulfillment: Lyophilized vials dispatched via same-day shipping (Monday–Friday) from distribution facilities in California and Arizona.
CJC-1295 DAC is supplied as a sterile, lyophilized cake inside glass vials sealed with flip-off aluminum crimp caps. To maintain peptide integrity during reconstitution, laboratory personnel should adhere to standardized aseptic techniques within a laminar flow hood.
Recommended reconstitution steps for laboratory analysis:
• Reagent Selection: Reconstitute using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose experimental protocol preservation or Sterile Saline (0.9% NaCl) for immediate in vitro application.
• Solvent Addition: Gently introduce the diluent along the internal glass wall of the vial using a sterile, low-retention syringe to avoid high-shear mechanical agitation.
• Dissolution Technique: Allow the solvent to naturally saturate the lyophilized powder, gently swirling the vial in a smooth circular motion. Do not shake or vortex vigorously, as physical shear stress can induce peptide denaturation or aggregation.
• Final Inspection: Confirm complete dissolution. The resulting solution should be completely clear, colorless, and free of particulate matter prior to micropipetting into assay media.
Lyophilized CJC-1295 DAC exhibits superior structural stability when stored under proper thermal conditions. Unreconstituted vials should be preserved at -20°C in a manual defrost freezer, protected from light exposure and humidity. Under these conditions, the desiccated peptide retains analytical stability for up to 24 months.
Upon reconstitution, the peptide becomes significantly more susceptible to hydrolytic cleavage and thermal degradation. Reconstituted liquid aliquots must be stored at 2°C to 8°C and utilized within 28 days if reconstituted with bacteriostatic water. For extended experimental timelines exceeding 30 days, reconstituted stock solutions should be divided into single-use micro-aliquots and stored at -80°C to avoid damaging freeze-thaw cycles. Detailed storage stability guidelines across our product lines are available in the PX1 research library.
For research institutions, university departments, and biotechnology firms requiring high-volume supplies of growth hormone secretagogues, PX1 Research offers streamlined institutional procurement. Setting up wholesale research accounts provides institutional buyers with dedicated account managers, bulk lot reservations, custom aliquot sizing, and standardized batch production schedules.
By sourcing directly from a US-based manufacturer, research facilities eliminate international customs delays, import tariff complications, and the analytical uncertainty associated with unverified overseas vendors. All orders placed before 3:00 PM PST Monday through Friday ship same-day from our dual logistics hubs in California and Arizona.
What does cjc 1295 dac vendita online refer to in scientific procurement?
The term 'cjc 1295 dac vendita online' describes the international procurement of research-grade CJC-1295 with Drug Affinity Complex via online supplier channels. It specifies laboratory-use reagents intended strictly for in vitro and animal research evaluating GHRH receptor activation and somatotropic signaling.
What is the primary function of the Drug Affinity Complex (DAC) in CJC-1295?
The DAC moiety consists of a maleimido derivative attached to the C-terminal lysine of the peptide. In biological environments, it forms a covalent bond with free cysteine-34 on serum albumin, extending the peptide's circulating plasma half-life to 6–8 days by preventing rapid enzymatic breakdown by DPP-IV and delaying renal clearance.
How does CJC-1295 DAC differ from CJC-1295 Without DAC?
CJC-1295 Without DAC (Modified GRF 1-29) lacks the maleimide linker and exhibits a short plasma half-life of approximately 30 minutes, leading to acute, pulsatile GH release. CJC-1295 with DAC binds to albumin, maintaining prolonged GHRH receptor stimulation and elevating baseline GH and IGF-1 levels over days.
Is CJC-1295 DAC intended for human therapeutic use or clinical administration?
No. CJC-1295 DAC supplied by PX1 Research is strictly designated for laboratory research, in vitro assays, and preclinical animal studies. It is not licensed, labeled, or intended for human consumption, medical diagnosis, treatment, or clinical administration.
What purity levels are guaranteed for PX1 Research CJC-1295 DAC?
Every lot of CJC-1295 DAC undergoes rigorous analytical verification achieving >99.0% chemical purity, verified via High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (ESI-MS). Each batch is accompanied by an official, downloadable Certificate of Analysis.
What are the endotoxin thresholds for research peptides at PX1 Research?
PX1 Research enforces strict endotoxin safety limits, guaranteeing levels below <0.01 EU/mg as measured by recombinant Factor C assays. This ensures compatibility with sensitive cell cultures and in vivo animal models.
Which diluent should be used to reconstitute CJC-1295 DAC for laboratory testing?
Reconstitution is typically performed using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) for repeated sampling protocols or Sterile 0.9% Sodium Chloride Solution for immediate, single-use in vitro assays.
How should lyophilized and reconstituted CJC-1295 DAC be stored?
Unopened lyophilized vials should be stored desiccated at -20°C or -80°C for long-term stability. Once reconstituted, the liquid solution should be refrigerated at 2°C–8°C and used within 28 days, or micro-aliquoted and stored at -80°C to prevent freeze-thaw degradation.
Where are PX1 Research peptides manufactured and dispatched from?
All PX1 Research peptides are manufactured in US-based, GMP-compliant, ISO 17025 accredited laboratories. Orders are fulfilled and shipped same-day (Monday through Friday) from our logistics centers in California and Arizona.
Can CJC-1295 DAC be co-administered with GHRPs in preclinical research?
Yes. Preclinical research literature commonly documents the co-application of GHRH analogs like CJC-1295 DAC with GHSR-1a agonists like Ipamorelin or GHRP-2 to investigate synergistic growth hormone release pathways and dual-receptor somatotrope activation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.